Immune Response good News - einsteigen ???? - 500 Beiträge pro Seite

[03516]

Hier der neuste Bericht von Immune Response. Sollte man da einsteigen ??


News




Clinical Data on REMUNE(TM) (Investigational HIV-1 Immunogen) Selected as a Late Breaker Presentation at the XIII International AIDS Conference in Durban, South Africa

Preliminary Results Suggest the Investigational Use of HIV Immune-Based
Therapy Alone or in Combination With Antiviral Drugs to Treat
HIV-Infected Individuals

CARLSBAD, Calif., July 14 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today that Trinity Medical Group, the Company`s
licensee for development of REMUNE in Southeast Asia, has informed the Company
that follow-up data from the Phase II clinical trial conducted in Thailand
were presented at the XIII International AIDS Conference in Durban, South
Africa.
In a late-breaker oral presentation, Vina Churdboonchart, Ph.D., of
Mahidol University, Bangkok, Thailand, reported an update on preliminary
results from a follow-up study of HIV-infected people who were previously
enrolled in a 40-week Phase II trial of Remune in Thailand for which she was
the Principal Investigator. The main objective of the Phase II trial was to
determine the effect of Remune as a monotherapy on CD4 helper T cells, which
are the primary targets of HIV. Patients treated with Remune had
significantly higher CD4 counts (an average increase of 84 CD4 cells) compared
to the placebo group at the end of the 40-week placebo controlled trial.
Furthermore, the increase in CD4 cells was associated with increased immune
activity against the virus, as measured by delayed type hypersensitivity skin
tests (a measure of cell mediated immunity against HIV) and western blot (a
measure of antibodies against HIV).
Upon conclusion and unblinding of the Phase II trial, all patients were
allowed to participate in an on-going open-label extension study with
continued Remune treatments every 12 weeks without concomitant antiviral drug
therapy. Patients are being monitored for changes in immune responses,
including number of CD4 helper T cells (specialized white blood cells), in
addition to body weight (an indicator of general health) and viral load (the
amount of replicating HIV in the bloodstream).
A total of 27 HIV-infected patients participating in the open-label study
have completed an additional 96 weeks (total of 136 weeks) of receiving Remune
as a monotherapy. Results were reported as a comparison of measurements taken
at baseline (at the conclusion of the original 40-week trial) and at
136 weeks. For the entire group, on average, CD4 counts increased by
100 cells, body weight increased by 1.05 kilograms, and viral load remained
stable (4,800 copies HIV RNA per mL at baseline vs. 4,700 copies HIV RNA per
mL at 136 weeks).
"At the end of the 40-week trial, patients treated with Remune experienced
a significant increase in CD4 cells compared to the placebo group. In the
subset of patients reaching 136 weeks, we are seeing an even greater increase
in CD4 cells with specific activity against HIV, which suggests that improved
immune responses may be the result of prolonged treatment with Remune," said
Dr. Churdboonchart. "Equally notable is that even without antiviral drug
therapy, viral load has remained stable on average for nearly three years in
this subset of patients." Dr. Churdboonchart added that the patients selected
for the Phase II trial were asymptomatic and relatively healthy individuals,
such that the observed positive immune responses to treatment with Remune
underscore the importance of early intervention to management of HIV
infection.
"These data are particularly relevant for this year`s AIDS meeting in
Africa as they suggest one potential strategy for slowing the AIDS epidemic in
developing countries where access to antivirals is limited," Dr.
Churdboonchart continued. "These results support our proposal to Thai health
authorities that Remune should be used as a first line therapy, with
cost-effective antivirals added on for non-responding patients. The stability
of these patients receiving REMUNE alone is comparable to that of clinical
non-progressors. These new data will be submitted to the Thai Ministry of
Public Health (the Thai FDA)."

The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T cell responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy that is designed to enable the intravenous injection of genes
for delivery to the liver.

NOTE: News releases for The Immune Response Corporation are available
through PR Newswire Company News On-Call fax service. For a menu of available
news releases or to retrieve a specific release made by The Immune Response
Corporation, please call 800-758-5804, extension 434675. Please retain these
numbers for future reference. Company information can also be located on the
Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether additional clinical trials will be
successfully concluded and whether Remune will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation`s SEC filings, including but not limited to
its report on Form 10-K for the year ended December 31, 1999 and subsequent
forms 10-Q. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

Remune (TM) is a trademark of The Immune Response Corporation.

SOURCE The Immune Response Corporation







Web site: http://www.imnr.com


Company News On-Call: http://www.prnewswire.com/comp/434675.htmlor fax, 800-758-5804, ext. 434675


CONTACT: Kathy Lane of The Immune Response Corporation,760-771-2236

[gimmequote!]

sehr interessant, mach mal in deitsch bitte!

gimmequote!

[topfit]

Entsprechnde Meldung aus aktiencheck.de:


Auf der 13. Internationalen AIDS Konferenz in Durban, Südafrika, die Immune
Response (WKN 879428) in einer Studie die erfolgversprechenden Daten einer
laufenden Phase II gegen HIV vorgestellt.

In besagter Studie konnte die Stimmulierung von Killer T-Zellen bei HIV
Patienten durch Remune TM in Kombination mit einer Antiviral Therapie
festgestellt werden. Diese Zellen besitzen nach Informationen von Professor
Eduardo Fernandz-Cruz die Fähigkeit, Zellen zu töten, die ein HIV-Antigen
aufweisen.

Entgegen dem negativen Trend der Biotechnologiewerte konnte Immune Response gestern 3,95 Prozent auf 11,50 Dollar zulegen.

[03516]

INVESTOR RELATIONS
News




The Immune Response Corporation Granted U.S. Patent For Targeting and Vaccinating With T Cell Receptor Peptides

Patent Covers Combination of Key Protein Sequences in Company`s
Investigational Immune-based Product for the Treatment of Rheumatoid Arthritis

CARLSBAD, Calif., Aug. 9 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today that it has received United States Patent
Number 6,090,387 covering methods and compositions relating to its
immune-based technology for the prevention and/or treatment of rheumatoid
arthritis. The patent includes specific claims covering a combination of key
protein sequences (peptides) from the Vbeta 3, Vbeta 14 and Vbeta 17 regions
present on the surface of aberrant T cells associated with joint destruction
in rheumatoid arthritis. By vaccinating with a combination of Vbeta 3, Vbeta
14 and Vbeta 17 peptides, the Company believes its product may inhibit the
disease-associated T cells and may prevent further damage.
"This is a key patent in that it directly covers the composition of IR501,
our investigational therapeutic vaccine in development to treat rheumatoid
arthritis," said Richard Bartholomew, Ph.D., Executive Director, Research
Operations, of The Immune Response Corporation. "The issuance of this patent
serves to further strengthen our comprehensive intellectual property position
in the field of T cell receptor peptide vaccine research."
The Company has successfully completed two Phase 2 clinical trials in
rheumatoid arthritis using this proprietary immune-based therapy. In a Phase
2b clinical trial of 340 rheumatoid arthritis patients with active disease,
the Company`s investigational product demonstrated safety and tolerability,
and suggested a statistically significant treatment effect using criteria
established by the American College of Rheumatology.
Several autoimmune disorders, including rheumatoid arthritis, psoriasis
and multiple sclerosis, result from the proliferation of misdirected T cells
that incorrectly identify and destroy the individual`s own tissue, such as the
lining of joints in rheumatoid arthritis. The Company`s proprietary
technology seeks to identify unique T cell receptors (TCRs), which are
proteins found on the surface of these autoreactive pathogenic T cells.
Patients are then vaccinated with portions of these TCR proteins, called TCR
peptides, which are specific to these autoreactive T cells. The Company
believes that this therapy may induce the immune system to eliminate or
inhibit the aberrant T cells without affecting other normal cells.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.

NOTE: News releases for The Immune Response Corporation are available
through PR Newswire Company News On-Call fax service. For a menu of available
news releases or to retrieve a specific release made by The Immune Response
Corporation, please call 800-758-5804, extension 434675. Please retain these
numbers for future reference. Company information can also be located on the
Internet Web Site: http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether our patents will be enforceable,
whether additional clinical trials will be successfully concluded and whether
any potential product(s) will be approved for marketing or be successfully
commercialized and those factors discussed more thoroughly in The Immune
Response Corporation`s SEC filings, including but not limited to its report on
Form 10-K for the year ended December 31, 1999 and subsequent Forms 10-Q. The
Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements which may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

SOURCE The Immune Response Corporation







Web site: http://www.imnr.com


Company News On-Call: http://www.prnewswire.com/comp/434675.htmlor fax, 800-758-5804, ext. 434675


CONTACT: Kathy Lane, Investor Relations of The Immune ResponseCorporation, 760-771-2236